| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8212436 | International Journal of Radiation Oncology*Biology*Physics | 2017 | 27 Pages |
Abstract
The effectiveness of SABR was the same for the elderly as for the average-age population according to lung cancer-specific survival and time-to-progression. It also poses no increased toxicity. Compared with the historical outcomes with surgery in the elderly, SABR outcomes can be considered comparable for stage I-II disease but with less morbidity.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Eric D. MD, MHS, Bing MD, Lina MD, Ritsuko MD, Zhonxing MD, Melenda MD, James W. MD, Michael S. MD, PhD, Daniel R. MD, Stephen M. MD, John V. MD, PhD, David C. MD, Joe Y. MD, PhD,